Bio-Rad Laboratories, Inc. $BIO Shares Acquired by JPMorgan Chase & Co.

JPMorgan Chase & Co. lifted its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 4.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 56,250 shares of the medical research company’s stock after purchasing an additional 2,519 shares during the period. JPMorgan Chase & Co. owned about 0.21% of Bio-Rad Laboratories worth $15,772,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the business. Quent Capital LLC purchased a new stake in Bio-Rad Laboratories during the 3rd quarter worth about $25,000. Farther Finance Advisors LLC raised its position in shares of Bio-Rad Laboratories by 52.9% during the 3rd quarter. Farther Finance Advisors LLC now owns 104 shares of the medical research company’s stock worth $29,000 after acquiring an additional 36 shares in the last quarter. Geneos Wealth Management Inc. lifted its stake in Bio-Rad Laboratories by 115.2% during the second quarter. Geneos Wealth Management Inc. now owns 142 shares of the medical research company’s stock worth $34,000 after purchasing an additional 76 shares during the last quarter. CWM LLC boosted its holdings in Bio-Rad Laboratories by 82.0% in the third quarter. CWM LLC now owns 202 shares of the medical research company’s stock valued at $57,000 after purchasing an additional 91 shares in the last quarter. Finally, UMB Bank n.a. increased its stake in Bio-Rad Laboratories by 24.0% in the third quarter. UMB Bank n.a. now owns 207 shares of the medical research company’s stock valued at $58,000 after purchasing an additional 40 shares during the last quarter. Hedge funds and other institutional investors own 65.24% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on BIO. Wall Street Zen cut shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Bio-Rad Laboratories in a report on Monday, December 29th. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $358.50.

Bio-Rad Laboratories Price Performance

Shares of BIO opened at $280.73 on Wednesday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.19 and a current ratio of 5.62. Bio-Rad Laboratories, Inc. has a fifty-two week low of $211.43 and a fifty-two week high of $343.12. The firm has a 50-day simple moving average of $297.25 and a 200-day simple moving average of $301.46. The company has a market capitalization of $7.58 billion, a price-to-earnings ratio of 10.06 and a beta of 1.18.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings data on Thursday, February 12th. The medical research company reported $2.51 EPS for the quarter, missing the consensus estimate of $2.57 by ($0.06). Bio-Rad Laboratories had a net margin of 29.42% and a return on equity of 3.86%. The company had revenue of $693.20 million for the quarter, compared to analysts’ expectations of $694.64 million. During the same period in the prior year, the company earned $2.90 earnings per share. The firm’s revenue was up 3.9% on a year-over-year basis. On average, equities research analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current year.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.